264 related articles for article (PubMed ID: 30070347)
1. Diagnostic value of F-18 FDG PET/CT for local and distant disease relapse surveillance in surgically treated RCC patients: Can it aid in establishing consensus follow up strategy?
Elahmadawy MA; Elazab MSS; Ahmed S; Salama M
Nucl Med Rev Cent East Eur; 2018; 21(2):85-91. PubMed ID: 30070347
[TBL] [Abstract][Full Text] [Related]
2. Significance of 18F-fluorodeoxyglucose positron-emission tomography/computed tomography for the postoperative surveillance of advanced renal cell carcinoma.
Park JW; Jo MK; Lee HM
BJU Int; 2009 Mar; 103(5):615-9. PubMed ID: 19007371
[TBL] [Abstract][Full Text] [Related]
3. F-18 fluorodeoxyglucose positron emission tomography in the evaluation of distant metastases from renal cell carcinoma.
Majhail NS; Urbain JL; Albani JM; Kanvinde MH; Rice TW; Novick AC; Mekhail TM; Olencki TE; Elson P; Bukowski RM
J Clin Oncol; 2003 Nov; 21(21):3995-4000. PubMed ID: 14581422
[TBL] [Abstract][Full Text] [Related]
4. Clinical utility of FDG PET/CT for primary and recurrent papillary renal cell carcinoma.
Hou G; Zhao D; Jiang Y; Zhu Z; Huo L; Li F; Cheng W
Cancer Imaging; 2021 Feb; 21(1):25. PubMed ID: 33632314
[TBL] [Abstract][Full Text] [Related]
5. A prospective diagnostic accuracy study of F-18 fluorodeoxyglucose-positron emission tomography/computed tomography in the evaluation of indeterminate renal masses.
Ozülker T; Ozülker F; Ozbek E; Ozpaçaci T
Nucl Med Commun; 2011 Apr; 32(4):265-72. PubMed ID: 21301376
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic performance of 18F-FDG PET/contrast-enhanced CT versus contrast-enhanced CT alone for post-treatment detection of ovarian malignancy.
Tawakol A; Abdelhafez YG; Osama A; Hamada E; El Refaei S
Nucl Med Commun; 2016 May; 37(5):453-60. PubMed ID: 26745811
[TBL] [Abstract][Full Text] [Related]
7. Clinical utility of
Nakamoto Y; Ishimori T; Shimizu Y; Sano K; Togashi K
Eur J Nucl Med Mol Imaging; 2019 Jul; 46(7):1524-1530. PubMed ID: 30847538
[TBL] [Abstract][Full Text] [Related]
8. F-18 fluorodeoxyglucose positron-emission tomography in the diagnosis of tumor recurrence and metastases in the follow-up of patients with breast carcinoma: a comparison to conventional imaging.
Gallowitsch HJ; Kresnik E; Gasser J; Kumnig G; Igerc I; Mikosch P; Lind P
Invest Radiol; 2003 May; 38(5):250-6. PubMed ID: 12750613
[TBL] [Abstract][Full Text] [Related]
9. Recurrent renal cell carcinoma: clinical and prognostic value of FDG PET/CT.
Alongi P; Picchio M; Zattoni F; Spallino M; Gianolli L; Saladini G; Evangelista L
Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):464-73. PubMed ID: 26268680
[TBL] [Abstract][Full Text] [Related]
10. The role of
Angelini A; Ceci F; Castellucci P; Graziani T; Polverari G; Trovarelli G; Palmerini E; Ferrari S; Fanti S; Ruggieri P
Eur J Nucl Med Mol Imaging; 2017 Sep; 44(10):1712-1720. PubMed ID: 28405727
[TBL] [Abstract][Full Text] [Related]
11. Role of F-18 FDG PET/CT in the follow-up of asymptomatic renal cell carcinoma patients for postoperative surveillance: based on conditional survival analysis.
Park S; Lee HY; Lee S
J Cancer Res Clin Oncol; 2022 Jan; 148(1):215-224. PubMed ID: 34106327
[TBL] [Abstract][Full Text] [Related]
12. The potential clinical value of FDG-PET for recurrent renal cell carcinoma.
Nakatani K; Nakamoto Y; Saga T; Higashi T; Togashi K
Eur J Radiol; 2011 Jul; 79(1):29-35. PubMed ID: 20015602
[TBL] [Abstract][Full Text] [Related]
13. Role of FDG PET-CT in recurrent renal cell carcinoma.
Kumar R; Shandal V; Shamim SA; Jeph S; Singh H; Malhotra A
Nucl Med Commun; 2010 Oct; 31(10):844-50. PubMed ID: 20661166
[TBL] [Abstract][Full Text] [Related]
14. Clinical role of F-18 fluorodeoxyglucose positron emission tomography for detection and management of renal cell carcinoma.
Ramdave S; Thomas GW; Berlangieri SU; Bolton DM; Davis I; Danguy HT; Macgregor D; Scott AM
J Urol; 2001 Sep; 166(3):825-30. PubMed ID: 11490227
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic performance and prognostic value of preoperative
Chen S; Zhao Y; Tang Q; Wu C; Wang A; Ma L; Zhang X; Chen J; Gao Y; Liao X; Feng N; Fan Y; Zhang J; Li X; Liu M
Cancer Imaging; 2022 Nov; 22(1):65. PubMed ID: 36435856
[TBL] [Abstract][Full Text] [Related]
16. Role of contrast-enhanced 18F-FDG PET/CT imaging in the diagnosis and staging of renal tumors.
Gündoğan C; Çermik TF; Erkan E; Yardimci AH; Behzatoğlu K; Tatar G; Okçu O; Toktaş MG
Nucl Med Commun; 2018 Dec; 39(12):1174-1182. PubMed ID: 30234688
[TBL] [Abstract][Full Text] [Related]
17. Restaging clear cell renal carcinoma with 18F-FDG PET/CT.
Fuccio C; Ceci F; Castellucci P; Spinapolice EG; Palumbo R; D'Ambrosio D; Bernardo A; Brunocilla E; Schiavina R; Maffione AM; Chondrogiannis S; Grassetto G; Colletti PM; Rubello D; Fanti S; Trifirò G
Clin Nucl Med; 2014 Jun; 39(6):e320-4. PubMed ID: 24566409
[TBL] [Abstract][Full Text] [Related]
18. Positron emission tomography/computed tomography with 18fluoro-deoxyglucose in the detection of local recurrence and distant metastases of pediatric sarcoma.
Arush MW; Israel O; Postovsky S; Militianu D; Meller I; Zaidman I; Sapir AE; Bar-Shalom R
Pediatr Blood Cancer; 2007 Dec; 49(7):901-5. PubMed ID: 17252575
[TBL] [Abstract][Full Text] [Related]
19. Comparison of 18F-DCFPyL and 18F-FDG PET/computed tomography for the restaging of clear cell renal cell carcinoma: preliminary results of 15 patients.
Liu Y; Wang G; Yu H; Wu Y; Lin M; Gao J; Xu B
Nucl Med Commun; 2020 Dec; 41(12):1299-1305. PubMed ID: 32941403
[TBL] [Abstract][Full Text] [Related]
20. Clinical utility of F-18 FDG PET/CT in recurrent breast carcinoma.
Manohar K; Mittal BR; Senthil R; Kashyap R; Bhattacharya A; Singh G
Nucl Med Commun; 2012 Jun; 33(6):591-6. PubMed ID: 22334135
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]